Murtuza Rampurwala to Cost-Benefit Analysis
This is a "connection" page, showing publications Murtuza Rampurwala has written about Cost-Benefit Analysis.
Connection Strength
0.575
-
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. PLoS One. 2019; 14(6):e0217778.
Score: 0.575
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.